Updates

3rd July, 2026 BSE Limited National Stock Exchange of India Limited P. J. Towers, Dalal Street, Exchange Plaza, Bandra Kurla Complex, Fort, Mumbai – 400 001 Bandra (East), Mumbai – 400 051 BSE Scrip Code: 543635 NSE Symbol: PPLPHARMA Sub: Business Responsibility & Sustainability Report for the Financial Year 2025-26 Dear Sir / Madam, Pursuant to Regulation 34(2)(f) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are submitting herewith, Business Responsibility & Sustainability Report along with Independent Auditor’s (Limited) Assurance Report provided by DNV Business Assurance India Pvt Ltd., which forms part of the Annual Report for the Financial Year 2025- Kindly take the above on record and oblige. Thank you. Yours sincerely, For Piramal Pharma Limited Maneesh Sharma Company Secretary & Compliance Officer Encl.: a/a Piramal Pharma Limited CIN: L24297MH2020PLC338592 Registered Office: Ananta Building, Piramal Corporate Park, Opp. Fire Brigade, Kamani Junction, LBS Marg, Kurla (West), Mumbai, Maharashtra, 400070 T: +91 22 3802 3000 / 4000; Email: shareholders.ppl@piramal.com www.piramalpharma.com Corporate Performance Advancing Management Statutory Financial Overview Overview Sustainability at Piramal Discussion and Analysis Reports Statements Business Responsibility and Sustainability Report Section A: General Disclosures I. Details of the listed entity 1. Corporate Identity Number (CIN) of the Company L24297MH2020PLC338592 2. Name of the Company Piramal Pharma Limited (the ‘Company’ or ‘PPL’) 3. Year of Incorporation 2020 4. Registered office address Ananta Building, Piramal Corporate Park, Opp. Fire Brigade, Kamani Junction, LBS Marg, Kurla (West), Mumbai - 400070. 5. Corporate office address Ananta Building, Piramal Corporate Park, Opp. Fire Brigade, Kamani Junction, LBS Marg, Kurla (West), Mumbai - 400070. 6. E-mail shareholders.ppl@piramal.com 7. Telephone +91-22-3802 3000 / 4000 8. Website www.piramalpharma.com 9. Financial year for which reporting is being done April 1, 2025 to March 31, 2026 10. Name of the Stock Exchange(s) where shares are listed National Stock Exchange of India Limited (NSE) and BSE Limited (BSE) 11. Paid-up Capital ₹ 1,329.25 Crores 12. Name and contact details (telephone, email address) of the Mr. Ganesh Chandra Tripathy – Senior Vice President and Global person for BRSR Reporting Head – Sustainability & EHS +91-22-3802 3000/4000 Ganesh.Tripathy@piramal.com 13. Reporting boundary Consolidated-Basis 14. Name of assurance provider DNV Business Assurance India Pvt Ltd. 15. Type of assurance obtained BRSR Core (Limited) II. Products/Services 16. Details of business activities (accounting for 90% of the turnover): Sr. % of Turnover of the Description of Main Activity Description of Business Activity No. entity 1. Pharmaceuticals Manufacturing of pharmaceuticals, medicinal, chemical and botanical 100% products 17. Products/Services sold by the entity (accounting for 90% of the entity’s turnover): Sr. % of total turnover Product/Services NIC Code No. contributed 1. Manufacturing of pharmaceuticals, medicinal, chemical and botanical products 210 100% III. Operations 18. Number of locations where plants and/or operations/offices of the entity are situated: Location Number of plants Number of offices Total 1. National 91 24 33 2. International 7 12 19 1excluding associates Annual Report 2025-26 Piramal Pharma Limited Business Responsibility and Sustainability Report 19. Markets served by the entity: a. Number of locations Locations Number 1. National (Number of states) PAN India 2 International (Number of countries) Over 100 countries b. What is the contribution of exports as a percentage of the total turnover of the entity? 72.78% c. A brief on types of customers The Company offers a portfolio of diversified products and services through end-to-end manufacturing capabilities. The Company has the following business segments/units: Piramal Pharma Solutions (PPS), an Integrated Contract Development and Manufacturing Organization (CDMO): API and Formulations Piramal Critical Care (PCC), Complex Hospital Generics (CHG): Inhalation Anesthesia, Injectable Anesthesia and Pain Management, Intrathecal Therapy and other products Piramal Consumer Healthcare (PCH): Over the counter (OTC) brands Customers of the Company include distributors, pharmacy chains, hospitals, government institutions, retail consumers and other pharmaceutical companies. IV. Employees 20. Details as at the end of Financial Year: a. Employees and workers (including differently abled): Sr. Male Female Particulars Total (A) No. No (B) % (B/A) No (C) % (C/A) Employees 1. Permanent (D) 6,617 5,259 79% 1,358 21% 2. Other than permanent (E) 157 63 40% 94 60% 3. Total employees (D + E) 6,774 5,322 79% 1,452 21% Workers 4. Permanent (F) 503 492 98% 11 2% 5. Other than Permanent (G) 3,163 2,592 82% 571 18% 6. Total workers (F + G) 3,666 3,084 84% 582 16% b. Differently abled Employees and workers: Sr. Male Female Particulars Total (A) No. No (B) % (B/A) No (C) % (C/A) Differently abled employees 1. Permanent (D) 2 2 100% 0 0% 2. Other than Permanent (E) 0 0 0% 0 0% 3. Total differently abled employees (D + E) 2 2 100% 0 0% Differently abled workers 4. Permanent (F) 0 0 0% 0 0.00% 5. Other than Permanent (G) 0 0 0% 0 0.00% 6. Total differently abled workers (F+G) 0 0 0% 0 0.00% Corporate Performance Advancing Management Statutory Financial Overview Overview Sustainability at Piramal Discussion and Analysis Reports Statements 21. Participation/Inclusion/Representation of women: No & % of Females Particulars1 Total (A) No (B) % (B/A) Board of Directors 10 3 30% Key Management Personnel2 4 2 50% 1On standalone basis 2Includes Key Management Personnel who are on the Board of Directors 22. Turnover rate for permanent employees and workers: FY 2026 FY 2025 FY 2024 Category Male (%) Female (%) Total (%) Male (%) Female (%) Total (%) Male (%) Female (%) Total (%) Permanent Employees 23% 21% 23% 25.34% 25.66% 25.50% 21.67% 24.08% 21.94% Permanent Workers 5% 9% 5% 4.52% 15.38% 4.78% 3.45% 6.90% 3.53%; V. Holding, Subsidiary and Associate Companies (including Joint ventures) 23. Names of holding / subsidiary / associate companies / joint ventures: Indicate whether Does the entity indicated at S. Name of the holding / subsidiary / associate holding/ Subsidiary/ % of shares held column A, participate in the No. companies / joint ventures (A) Associate/ Joint by listed entity1 Business Responsibility initiatives Venture of the listed entity? (Yes/No) 1 Piramal Critical Care Deutschland GmbH Subsidiary 100 No (All these entities are 2 Piramal Critical Care Italia S.P.A. Subsidiary 100 unlisted) 3 Piramal Critical Care Limited Subsidiary 100 4 Piramal Healthcare UK Limited Subsidiary 100 5 Piramal Healthcare Pension Trustees Limited Subsidiary 100 6 Piramal Healthcare (Canada) Limited Subsidiary 100 7 Piramal Critical Care South Africa (PTY) Ltd. Subsidiary 100 8 Piramal Critical Care Pty. Ltd. Subsidiary 100 9 Piramal Critical Care B.V. Subsidiary 100 10 Piramal Dutch Holdings B.V.2 Subsidiary 100 11 Piramal Pharma Solutions (Dutch) B.V. Subsidiary 100 12 Piramal Pharma Inc. Subsidiary 100 13 Piramal Healthcare, Inc. Subsidiary 100 14 Piramal Critical Care, Inc. Subsidiary 100 15 Piramal Pharma Solutions Inc. Subsidiary 100 16 PPL Pharma Inc. Subsidiary 100 17 PPL Pharma Solutions Riverview LLC Subsidiary 100 18 PPL Healthcare LLC Subsidiary 100 19 Piramal Critical Care Single Member P.C. Subsidiary 100 20 Piramal Pharma II Private Limited Subsidiary 100 21 Piramal Pharma Limited Employees Welfare Trust Subsidiary 100 22 Abbvie Therapeutics India Private Limited Associate 49 23 Yapan Bio Private Limited Associate 33.33 Note: 1 Held directly or through subsidiary companies. 2 The name of Piramal Dutch Holdings N.V. was changed to Piramal Dutch Holdings B.V. w.e.f. December 29, 2025 VI. CSR details1 24. i. Whether CSR is [Showing first 8,000 characters — download PDF for full document]